Literature DB >> 6121546

Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics.

D G Owens, E C Johnstone, C D Frith.   

Abstract

Using two standardized recording techniques (the Abnormal Involuntary Movement Scale [AIMS] and the Rockland Scale), spontaneous involuntary movement disorder was assessed in a sample of 411 hospitalized patients with chronic schizophrenia, 47 of whom apparently had never been exposed to neuroleptic medication. Prevalence of abnormality clearly depended on the criteria of severity adopted, but overall it was high, with half of the sample on the AIMS and two thirds on the Rockland Scale rating 3 (moderate) or more on one item or more. Comparison of those with a history of treatment with neuroleptics and those with no such history showed few significant differences with regard to prevalence, severity, and distribution of abnormal involuntary movements. We concluded that spontaneous involuntary disorders of movement can be a feature of severe, chronic schizophrenia unmodified by neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121546     DOI: 10.1001/archpsyc.1982.04290040052008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  31 in total

1.  Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment.

Authors:  P R Buckland; M C O'Donovan; P McGuffin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

Authors:  L Peacock; T Solgaard; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.

Authors:  J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain.

Authors:  F Okada; T J Crow; G W Roberts
Journal:  J Neural Transm Gen Sect       Date:  1990

5.  Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables.

Authors:  O Gureje
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

Review 6.  The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders.

Authors:  Gabor S Ungvari; Stanley N Caroff; Jozsef Gerevich
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

7.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.

Authors:  Jeroen P F Koning; Diederik E Tenback; Jim van Os; André Aleman; René S Kahn; Peter N van Harten
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

8.  Tardive dystonia in a psychiatric hospital.

Authors:  J H Friedman; L T Kucharski; R L Wagner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

9.  Clinical correlates of postmortem brain changes in schizophrenia: decreased brain weight and length correlate with indices of early impairment.

Authors:  E C Johnstone; C J Bruton; T J Crow; C D Frith; D G Owens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

10.  Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: from mouse to man.

Authors:  D C German; D S Schlusselberg; D J Woodward
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.